Skip to main content

Table 6 AE-related disutilities included in the model [Source: [22]]

From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

 

Description

Disutility

Duration

Source

Additive disutility

Cataract

−0.142

1 month

(Brown et al. 2007) [22]

Endophthalmitis

−0.3

20% 1 year, 80% 1.5 months

Intraocular inflammation

−0.044

1 month

Detachment of the retina

−0.27

3 months

No disutility

Retinal pigment epithelial tear

−0.00

No impact

Retinal tear

−0.00

No impact